Your browser doesn't support javascript.
loading
Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects.
Huntjens, Dymphy R H; Ouwerkerk-Mahadevan, Sivi; Brochot, Anne; Rusch, Sarah; Stevens, Marita; Verloes, Rene.
Afiliação
  • Huntjens DRH; Global Clinical Pharmacology, Janssen Pharmaceutica NV, Beerse, Belgium. DHuntjes@its.jnj.com.
  • Ouwerkerk-Mahadevan S; Global Clinical Pharmacology, Janssen Pharmaceutica NV, Beerse, Belgium.
  • Brochot A; Global Clinical Pharmacology, Janssen Pharmaceutica NV, Beerse, Belgium.
  • Rusch S; Statistics and Decision Sciences, Janssen Pharmaceutica NV, Beerse, Belgium.
  • Stevens M; Global Clinical Development, Janssen Pharmaceutica NV, Beerse, Belgium.
  • Verloes R; Global Clinical Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Clin Pharmacokinet ; 56(11): 1331-1342, 2017 11.
Article em En | MEDLINE | ID: mdl-28238203
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Imidazolidinas / Indóis / Modelos Biológicos Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Imidazolidinas / Indóis / Modelos Biológicos Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article